Journal of Diabetes and Metabolic Disorders30ANTIBODY ANTIGLIADIN IN DIABETIC PATIENTS.5353ShahinYARAHMADIBagherLARIJANIEbrahimJAVADIMohammad-HassanBASTANHAGHMohammadPAJOUHIRezaMALEKZDEHMahmoodMAHMOODIAlierezaSHAFAEIMohammad-RezaMOHAJERI-TEHRANIAliRAJABIMohammadFARHADI20151005introduction:  Celiac disease and type1 diabetes mellitus have been linked to identical HLA markers and chromosomal loci, which may account for the co-occurrence of these two disorders in a significant subgroup of population.  We designed a study to investigate the frequency of gliadin antibodies, a marker for coeliac disease, in diabetic patients. methods: In this study 182 diabetic patients (52 with type1 and 130 with type2 diabetes) were screened for anti-gliadin IgG by indirect immunofluorescence. Age range was 3-29.5 and 42-65 years for   type 1 and   type 2 diabetes groups. results: Anti-gliadin IgG was positive in1.9% and 1.5% of patients with   type 1and type 2 diabetes. The reported frequency of anti-gliadin seropositivity is 0.02% among healthy blood donors in Tehran. Conclusion: The frequency of anti-gliadin seropositivity is 30 and 24 times higher in type 1 and type 2 diabetic patients, respectively, comparing with the general population of Tehran.  This concurs with reports elsewhere of the higher prevalence of coeliac disease in diabetic populations.  The relatively low sensitivity and specificity (both around 80%) of the gliadin antibody test makes it a less-than ideal- experimental diagnostic tool, but the IFI assay is quick and inexpensive and therefore suitable for population screening programs, which we recommend in all at-risk patients with diabetes.https://jdmd.tums.ac.ir/index.php/jdmd/article/view/53